Combining the amplification refractory mutation system and high-resolution melting analysis for KRAS mutation...

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Discovery

Background:

• Personalized medicine relies on identifying predictive biomarkers for targeted therapies.
• Tumor samples present challenges due to heterogeneity; liquid biopsies offer an alternative.
• Circulating tumor DNA (ctDNA) analysis is a promising tool for diagnosis and prognosis.

Purpose of the Study:

• To develop and validate an Amplification Refractory Mutation System (ARMS) coupled with High-Resolution Melting Analysis (HRMA) for KRAS mutation detection.
• To assess the sensitivity and specificity of ARMS-HRMA in tumor and plasma samples from pancreatic ductal adenocarcinoma (PDAC) patients.
• To compare ARMS-HRMA performance against Sanger sequencing (SS) and droplet digital polymerase chain reaction (ddPCR).

Main Methods:

• Optimization of ARMS-HRMA using commercial cancer cell lines.
• Validation of ARMS-HRMA for KRAS codon 12 mutation screening in tumor and plasma DNA.
• Comparative analysis with Sanger sequencing and ddPCR for mutation detection accuracy.

Main Results:

• ARMS-HRMA demonstrated high sensitivity and specificity for detecting KRAS mutations in both tumor and plasma samples.
• The method identified more mutations than SS and ddPCR in tumor DNA.
• ARMS-HRMA also outperformed SS and ddPCR in detecting mutations in ctDNA from plasma samples, despite limitations with genetic material quantity.

Conclusions:

• ARMS-HRMA is a simple, sensitive, and specific method for screening low-level mutations in liquid biopsies.
• This methodology can potentially enhance diagnostic and prognostic schemes in oncology.
• The developed ARMS-HRMA assay shows promise for routine clinical application in personalized medicine.